202 related articles for article (PubMed ID: 1867960)
1. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
Tyndale RF; Kalow W; Inaba T
Br J Clin Pharmacol; 1991 Jun; 31(6):655-60. PubMed ID: 1867960
[TBL] [Abstract][Full Text] [Related]
2. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol.
Pan L; Belpaire FM
Eur J Clin Pharmacol; 1999 Oct; 55(8):599-604. PubMed ID: 10541779
[TBL] [Abstract][Full Text] [Related]
3. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6.
Young D; Midha KK; Fossler MJ; Hawes EM; Hubbard JW; McKay G; Korchinski ED
Eur J Clin Pharmacol; 1993; 44(5):433-8. PubMed ID: 8359179
[TBL] [Abstract][Full Text] [Related]
4. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation.
Kudo S; Odomi M
Eur J Clin Pharmacol; 1998 May; 54(3):253-9. PubMed ID: 9681669
[TBL] [Abstract][Full Text] [Related]
5. In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol.
Pan LP; De Vriendt C; Belpaire FM
Pharmacogenetics; 1998 Oct; 8(5):383-9. PubMed ID: 9825830
[TBL] [Abstract][Full Text] [Related]
6. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
7. Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).
Pressacco J; Muller R; Kalow W
Eur J Clin Pharmacol; 1993; 45(3):261-4. PubMed ID: 8276051
[TBL] [Abstract][Full Text] [Related]
8. A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
Inaba T; Nakano M; Otton SV; Mahon WA; Kalow W
Can J Physiol Pharmacol; 1984 Jul; 62(7):860-2. PubMed ID: 6498616
[TBL] [Abstract][Full Text] [Related]
9. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
10. Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.
Muralidharan G; Hawes EM; McKay G; Midha KK
Xenobiotica; 1991 Nov; 21(11):1441-50. PubMed ID: 1763518
[TBL] [Abstract][Full Text] [Related]
11. The metabolism of tamoxifen by human liver microsomes is not mediated by cytochrome P450IID6.
Blankson EA; Ellis SW; Lennard MS; Tucker GT; Rogers K
Biochem Pharmacol; 1991 Dec; 42 Suppl():S209-12. PubMed ID: 1768279
[No Abstract] [Full Text] [Related]
12. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man.
Kobayashi S; Murray S; Watson D; Sesardic D; Davies DS; Boobis AR
Biochem Pharmacol; 1989 Sep; 38(17):2795-9. PubMed ID: 2775304
[TBL] [Abstract][Full Text] [Related]
13. Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro.
Tyndale RF; Inaba T; Kalow W
Drug Metab Dispos; 1989; 17(3):334-40. PubMed ID: 2568917
[TBL] [Abstract][Full Text] [Related]
14. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol.
Fang J; Baker GB; Silverstone PH; Coutts RT
Cell Mol Neurobiol; 1997 Apr; 17(2):227-33. PubMed ID: 9140699
[TBL] [Abstract][Full Text] [Related]
15. Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?
Chang WH
Psychopharmacology (Berl); 1992; 106(3):289-96. PubMed ID: 1570373
[TBL] [Abstract][Full Text] [Related]
16. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
Ellis SW; Ching MS; Watson PF; Henderson CJ; Simula AP; Lennard MS; Tucker GT; Woods HF
Biochem Pharmacol; 1992 Aug; 44(4):617-20. PubMed ID: 1510710
[TBL] [Abstract][Full Text] [Related]
17. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
18. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
Brosen K
Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
[TBL] [Abstract][Full Text] [Related]
20. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.
Pan L; Vander Stichele R; Rosseel MT; Berlo JA; De Schepper N; Belpaire FM
Ther Drug Monit; 1999 Oct; 21(5):489-97. PubMed ID: 10519444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
